Clean Sweep Live Auction on Wed. February 27th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Cardiology Homepage

John D. Zehren Endologix appoints chief commercial officer

Medtronic to acquire EPIX Therapeutics Will use EPIX's cardiac ablation technology with Medtronic's cryoballoon technology

Centerline Biomedical submits IOPS system for FDA clearance Designed as alternative to X-ray fluoroscopy

Philips unveils Azurion angiography system with FlexArm positioning System moves on eight different axes with single controller

FDA clears RFPi's iCertainty blood flow and perfusion imaging solution No injections, dyes, radiation, direct patient contact or interruptions in procedures

Rob Beanlands ASNC names president for 2019

FDA gives nod to new clearance for iSchemaView’s RAPID platform Can help select which stroke patients require clot removal procedures

Hill-Rom Holdings launches LINQ Mobile App that connects care team members to one another, patients and patient info in real time

FDA gives green light for Edwards' SAPIEN 3 Ultra system Provides transcatheter aortic valve replacement to patients facing surgical risks

Boston Scientific to acquire shares of Millipede for $325 million Initially bought $90 million worth of shares a year ago

MaxQ-AI is intending to create a
public $8 million IPO listing
on Nasdaq

MaxQ-AI seeks $8 million public IPO listing on Nasdaq

AI software developer MaxQ-AI is expected to go public in the near future, establishing an $8 million IPO listing on the Nasdaq, according to an S-1 registration statement.

The decision to do so by the Israel-based enterprise, known for developing AI tools to aid in diagnostic imaging of the brain, is part of its initiative to assist in the FDA regulatory processes for clearance of its Accipio software portfolio, viewing such a status as essential in helping to avoid repeats of net losses suffered over the last few years. It follows the recent CE marking of its AccipioIx intracranial hemorrhage AI platform.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510

“In May 2018, our AccipioIx product received CE mark approval. None of our other products have been approved for commercial sale by regulatory authorities. We will not be able to generate revenues for our other products, or generate revenues for any products in the United States, until we obtain those approvals,” MaxQ-AI said in its registration statement. We have experienced net losses since our inception and had net losses of $9.2 and $1.9 million in fiscal year 2017 and in the first quarter of 2018, respectively. Our auditors have expressed doubt about our ability to continue as a going concern unless we are able to raise equity or debt financing."

The Accipio portfolio is composed of three solutions, including AccipioDx, a CT diagnostic tool that enables clinicians to determine the presence of strokes or traumatic brain injuries with the detection of intracranial bleeding; AccipioIx, a workflow-prioritization system that alerts clinicians to potential bleeds and their locations; and AccipioAx, designed to provide annotated images and 3D renderings of the brain based on original scans for evaluation.

Its decision comes just months after another made in April to change the company’s name from MedyMatch Technology in an effort to bring AI clinical applications to the market.

Prior to this, the company received Expedited Access Pathway (EAP) designation from the FDA for its intracranial hemorrhage detection software.

It also engaged in a number of partnerships with Samsung Neurologica, which agreed to integrate the ICH detection application into its 8-slice small-bore CereTom portable CT scanner; IBM Watson Health for distribution through IBM’s vendor-neutral sales channels for integration into its other offerings; and GE Healthcare for integration with its CT scanners.

“We believe that by leveraging the existing sales and marketing infrastructure of these channel partners, each of which is a leading medical equipment manufacturer, we will be able to achieve high market penetration and user adoption rates,” said MaxQ-AI in its statement. “We have not submitted any Accipio products for FDA approval, but we intend to do so commencing in the third quarter of 2018. We expect to receive FDA approval for AccipioIx during the fourth quarter of 2018, and we expect to receive FDA approval for AccipioDx as well as AccipioAx in 2019.”

MaxQ-AI declined HCB News’ request for comment. “We are in a quiet period right now and are unable to comment on the IPO,” Michael Rosenberg, chief commercial and financial officer for MaxQ-AI, said in an email.

In addition, the company expects CE mark approvals for AccipioAx and Dx in the first half of 2019.

Terms of the registration are not complete and subject to change.

Pricing terms were not disclosed.

Cardiology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.